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 More than 100 years ago, we started to 
realize that there are correlations between 
dietary sodium consumption and high 
blood pressure. When people left  tribal 
communities and became part of indus-
trial society, increased dietary sodium was 
accompanied by high blood pressure in 
one-third of them. 1 Th e concept of sodium 
sensitivity was born aft er this observation, 
and today we believe that the majority of 
essential hypertension fi ts into this cate-
gory. Furthermore, another series of 
experiments confirmed that a high-
sodium diet causes vascular damage even 
without changes in blood pressure. 2 
In addition to a signifi cant decrease in 
blood pressure by the Dietary Approaches 
to Stop Hypertension (DASH) diet, 
Bibbins-Domingo  et al. also projected sig-
nifi cant improvement in cardiovascular 
morbidity and mortality with dietary salt 
reduction. 3 
 Although compelling evidence has 
shown that high sodium intake is associated 
with high blood pressure, vascular damage, 
and higher mortality in the general popula-
tion, the evidence is still weak in patients on 
chronic hemodialysis. Mc Causland  et al. 4 
(this issue) have taken an important step by 
exploring the potential role of dietary 
sodium intake in mortality of patients on 
chronic hemodialysis. In this study, the 
authors undertook a  post hoc analysis of 
1770 subjects from the Hemodialysis 
(HEMO) Study on whom complete data 
were available. Th e dietary sodium intake, 
estimated on the basis of 2-day dietary 
assisted recalls, correlated with ultrafi ltra-
tion requirements, serum sodium, systolic 
blood pressure, and all-cause mortality. 
After case-mix adjustment, they found 
that higher dietary sodium intake was 
marginally associated with higher ultrafi l-
tration requirement and all-cause mortality. 
Interestingly, reported dietary sodium, 
sodium / calorie ratio, and sodium / 
potassium ratio were not associated with 
systolic blood pressure. Finally, there was 
no association between restrictive (    2  g / d) 
versus liberal (>2  g / d) sodium consumption 
and all-cause mortality. 4 
 Although this study uses data from a 
landmark experiment on hemodialysis 
patients (the HEMO Study), and the 
authors performed an excellent analysis to 
examine their hypothesis, there are some 
issues that are worth careful attention. 
Th e fi rst is the method of estimating die-
tary sodium. The HEMO Study used 
dietary recall to estimate sodium con-
sumption. Several studies have reported a 
weak correlation between 24-h dietary 
recall and 24-h urinary measurement of 
sodium. 5 In general, dietary recalls tend 
to underestimate total dietary sodium 
intake. 6 Furthermore, some people, espe-
cially on hemodialysis, may tend to under-
report their daily nutrient consumption 
and total calorie intake. Mc Causland 
 et al. 4 report that the mean caloric intake 
in the total cohort was 1523 ± 547  kcal / d. 
Given that malnourished patients (serum 
albumin   <  2.6  g / dl) had been excluded 
from the HEMO Study, this low caloric 
intake among the study population might 
be at least in part due to underreporting 
and / or underestimation of the total caloric 
intake. In this study, daily calorie intake 
was strongly associated with reported 
dietary sodium intake even aft er adjust-
ment for case mix and other confounders. 
Th ese fi ndings are mostly suggestive of 
underestimation of total dietary sodium 
by the participants in the HEMO Study. 
 Th e second concern is the magnitude of 
higher mortality risk seen with high 
sodium consumption compared with that 
of  ‘ recommended ’ dietary sodium of 
about 2  g / d. Only the fourth quartile of 
dietary sodium consumption was slightly 
associated with increased all-cause mor-
tality, when compared with the fi rst quar-
tile (and not with the  ‘ recommended ’ 
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dietary sodium of around 2  g / d, that is, the 
second and third quartiles). In other 
words, the mortality rate in the fourth 
quartile was not statistically signifi cantly 
higher than that seen with 2  g / d dietary 
sodium. Restricted cubic spline graphs 
also show a seemingly linear trend toward 
increased mortality with increasing die-
tary sodium. However, the 95 % confi-
dence interval of the spline graphs crosses 
the hazard ratio of 1, which again indi-
cates that the null hypothesis cannot be 
rejected. Furthermore, the dose-response 
trend seen in the cubic spline graphs in 
Mc Causland  et al. 4 indicates that the 
lower the dietary sodium, the better the 
survival. Th is observation is in sharp con-
trast with previous fi ndings that very low 
dietary sodium might indeed be associ-
ated with adverse outcomes in healthy 
people and dialysis patients (J-shaped or 
U-shaped association). 7 Even though the 
majority of mortality in hemodialysis 
patients is attributed to cardiovascular 
causes, a considerable proportion of 
deaths could still be attributed to another 
cause, such as infection. Th erefore, the 
association of dietary sodium and cardio-
vascular mortality, and not all-cause 
mortality, would be more relevant to 
pathophysiologic pathways of sodium 
regulation in hemodialysis patients. 
 Another important f inding of 
Mc Causland  et al. 4 is that the reported 
dietary sodium, sodium / calorie ratio, and 
sodium / potassium ratio were not asso-
ciated with systolic blood pressure. 
Th is fi nding raises the possibility that the 
concept of sodium sensitivity may not 
be applicable to chronic hemodialysis 
patients. Further investigations are needed 
to evaluate sensitivity to sodium in hemo-
dialysis patients. 
 Finally, the authors examined the asso-
ciation between restrictive (    2  g / d) versus 
liberal (>2  g / d) sodium consumption and 
all-cause mortality. Several factors may 
explain why this analysis did not show any 
signifi cant change in mortality between 
these two groups. First, this sodium restric-
tion was not randomized. Patients in the 
liberal sodium group were mostly men, 
consumed more calories and protein, and 
had better mid-arm muscle circumference 
and triceps skin-fold thickness. Poor 
adherence of the participants on sodium 
restriction might be another explanation 
as to why such intervention was not associ-
ated with improved survival. As discussed 
by the authors, mean dietary sodium was 
only 200  mg / d lower in patients on restric-
tive versus liberal sodium intake. Further-
more, the range of prescribed dietary 
sodium was very limited (2 versus 3 – 4 
g / d). Examining a wider range of dietary 
sodium prescription might be indicated to 
elucidate beneficial effects of sodium 
restriction. As the authors mention, these 
data do not support the idea that higher 
dietary sodium consumption (beyond 
3 – 4  g / d) is safe. Conversely, these data fail 
to show any harmful eff ect of even more 
liberal dietary sodium prescription. 
 Mother Nature did not originally design 
salt to be bad; humans have made sodium 
an adversary. Salmon and trout are two fi sh 
species that live in salt water as well as fresh 
water during their lifetimes. Th eir time in 
salt water is similar to a human ’ s high-
sodium diet, and their time in fresh water 
is somewhat similar to a human ’ s low-
sodium diet. During their time in salt 
water the fish ’ s kidneys produce small 
amounts of concentrated urine, whereas in 
fresh water they excrete a volume of dilute 
urine equivalent to one-third of their body 
weight per day. During the transition from 
fresh to salt water, fi sh adopt a new mech-
anism of using an increase in atrial natri-
uretic peptide and the renin – angiotensin 
system to maintain sodium balance. 8 Dur-
ing evolution, the human kidney has been 
well equipped to deal with high sodium 
intake more eff ectively than the fi sh kid-
ney. Th e stimulation of the thirst center to 
increase water intake and the increase of 
water reabsorption by the kidneys are the 
main defense mechanisms. In a normal 
physiologic setting these mechanisms are 
eff ective and potent. Th e majority of our 
patients on hemodialysis are elderly and 
not physiologically healthy. The thirst 
mechanism in the elderly is relatively 
blunted, and the kidney may not respond 
to arginine vasopressin and atrial natriu-
retic peptide as well as during youth. 9 In 
advanced chronic kidney disease, however, 
there are uncertainties concerning the fate 
of sodium. Recently, Hecking  et al. 
reported that with the use of sodium mod-
eling for every 2 mequiv. per liter higher 
than serum sodium level, all-cause mortal-
ity risk decreases by 12 % . 10 
 Th is paper by Mc Causland  et al. 4 is of 
signifi cant importance to both theoretical 
and clinical nephrology. However, numer-
ous questions still remain unanswered. 
Does high dietary sodium intake act the 
same in all subgroups of dialysis patients? 
Is the effect of a high-sodium diet the 
same in anuric versus normal urine out-
put? Is 2  g the best cutoff for dietary 
sodium consumption in the hemodialysis 
population? Does dietary sodium play a 
major role in nutritional interventions to 
treat protein-energy wasting? Does the 
aging process in hemodialysis patients 
make them salt sensitive? At the moment, 
the answers to these and several other 
questions remain uncertain. A strength of 
the study by Mc Causland  et al. 4 is that it 
introduces a pathophysiologic concept for 
future clinical experiments. Th is study 
suggests a need for well-designed clinical 
trials to examine the association of dietary 
sodium modifi cation and outcomes in 
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 Figure 1  |  Schematic representation of the causes of adverse outcomes and mortality in 
dialysis patients. 
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dialysis patients, especially when the evi-
dence supporting daily dietary sodium 
intake of 2  g is not strong. 
 In conclusion, the cardiovascular mor-
tality in the dialysis population is multifac-
torial, and high sodium intake is just one 
of the players in this context ( Figure 1 ). It 
took years to understand the role of dietary 
sodium in morbidity and mortality in 
healthy populations; in patients on chronic 
dialysis we are just at the beginning. 
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 Renal fi brosis is the underlying patho-
logical alteration and end point of most, if 
not all, progressive kidney diseases. Fibro-
sis is considered a uniform process defi ned 
as exaggerated deposition of non-
functional scar tissue comprising extracel-
lular matrix and (myo) fi broblasts. It is 
most oft en associated with injured or atro-
phied tubules and inflammatory infil-
trates. Understanding the mechanisms 
and molecules involved in renal fi brosis 
could lead to identifi cation of novel, eff ec-
tive treatments, which we are currently 
lacking. 1 Nakagawa and colleagues 2 
(this issue) present the fi rst step in the 
identifi cation of such a novel molecule: 
the prostaglandin E 2 receptor EP 4 . 2 
 Prostaglandin E 2 (PGE 2 ) is one of the 
major prostanoids and the most abundant 
one in the kidney. It is synthesized pre-
dominantly from arachidonic acid via the 
rate-limiting enzymes cyclooxygenase-1 
and -2 (COX-1 and -2) and prostaglandin 
E synthase ( Figure 1a ). All prostanoids 
bind to G protein-coupled receptors with 
seven transmembrane domains. PGE 2 has 
four receptors, termed EP 1 , EP 2 , EP 3 , and 
EP 4 . Each has a slightly diff erent down-
stream signaling ( Figure 1a ). 3 
 Nakagawa and colleagues 2 used the 
unilateral ureteral obstruction (UUO) 
model in mice, a widely used model of 
interstitial fi brosis. Th ey fi rst described 
the regulation of COX and EP receptors 
in obstructed kidneys compared with 
non-obstructed ones. COX enzymes are 
the rate-limiting step in prostanoid syn-
thesis, and their upregulation is a neces-
sary step in increased synthesis of these 
lipid mediators. In the obstructed kidneys, 
COX-2 mRNA was increased up to three-
fold already at day 1 of UUO and remained 
upregulated at this level thereaft er. Inter-
estingly, the authors also observed a slight 
but significant upregulation of COX-1 
mRNA, that is, of the isoform considered 
to be constitutively expressed. Th ese data 
further extend previous studies showing 
increased synthesis of prostanoids, includ-
ing PGE 2 , via increased COX expression 
in the UUO model. 4,5 Next the authors 
analyzed the expression of PGE 2 recep-
tors. EP 1 was not regulated whereas EP 2 
was signifi cantly increased on day 7, and 
EP 4 was even more strongly upregulated 
on both day 4 and day 7 aft er UUO. EP 3 , 
a receptor with antagonistic signaling 
compared with EP 2 and EP 4 ( Figure 1a ), 
was significantly downregulated at 
all examined time points. The authors 
also analyzed the localization of COX-2 
(by immunofl uorescence) and EP 4 (by 
 in situ hybridization). Both were nearly 
undetectable in normal kidneys, strongly 
upregulated in UUO kidneys, and mainly 
localized in tubular cells. Th e EP 4 signal 
was also observed in interstitial cells. In 
line with these  in vivo fi ndings, stimula-
tion of primary tubular cells with profi -
brotic transforming growth factor-  1 
induced EP 4 mRNA expression. Taken 
together, these results suggest that COX –
 PGE 2 – EP 4 represents an inducible system 
strongly upregulated during ureter 
obstruction. Interestingly, in another 
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 Most progressive and severe acute kidney diseases lead to renal fibrosis, 
for which we still lack effective treatment options. Prostaglandin E 2 
(PGE 2 ) is one of the most abundant prostanoids, exerting its pleiotropic 
functions via four receptors, EP 1 through EP 4 . Recent studies indicate 
that the PGE 2 – EP 4 pathway is a potent endogenous renoprotective 
system that limits renal fibrosis by acting on multiple cellular targets. 
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